CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts, and offering expenses.
